{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-22-001411","form_type":"8-K","ticker":"CFOR","cik":"0001293818","company_name":"CapForce Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.037867+00:00","generated_at":"2026-06-21T22:24:28.500298+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OpGen Q3 revenue drops to $0.4M from $1.2M; net loss $14.1M; cash down to $10.3M","bullets":["Total revenue $0.4M for Q3 2022 vs $1.2M in Q3 2021; net loss $14.1M ($0.30/sh) vs $6.1M loss.","Cash and equivalents $10.3M as of Sept 30, 2022, down from $36.1M at Dec 31, 2021.","Elected Yvonne Schlaeppi as independent director; she brings legal, governance, life sciences experience.","Completed enrollment of >1,800 samples for Unyvero UTI trial; anticipates FDA submission in 2023.","Full-year 2022 revenue guidance $2.5M to $3M; exploring additional financing and strategic alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-22-001411","json":"https://secwatch.observer/filing/0001079973-22-001411.json","markdown":"https://secwatch.observer/filing/0001079973-22-001411.md","text":"https://secwatch.observer/filing/0001079973-22-001411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293818/000107997322001411/0001079973-22-001411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293818/000107997322001411/opgen_8k-110922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:24:28.500298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"289dbe678c6faefdfd984531defd0900267e4f91","claim":"CapForce Inc. reported Full Year 2022 results: revenue approximately $2.5 to $3 million. Guidance initiated.","evidence_excerpt":"Overall, 2022 revenue in a range of approximately $2.5 to $3 million from products and services as well as collaboration business globally.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293818/000107997322001411/0001079973-22-001411-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Revenue","value":"approximately $2.5 to $3 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"d2f2e25bfd","claim":"Yvonne Schlaeppi was elected as Director at CapForce Inc..","evidence_excerpt":"On November 8, 2022, the Board of Directors of the Company (the “Board”) elected Yvonne Schlaeppi as a member of its Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293818/000107997322001411/0001079973-22-001411-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}